More recently, the combination of nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) has demonstrated strong anti-tumour activity in the neoadjuvant treatment of dMMR CRC, with a pathological response rate of 97% [22]. This evidence concerns the gene PDCD1 and neoplasm.